Medicenna Therapeutics Corp
MDNA
Company Profile
Business description
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Contact
2 Bloor Street West
Suite 903
TorontoONM4W 3E2
CANT: +1 416 964-5442
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
17
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,999.00 | 16.40 | -0.18% |
CAC 40 | 7,771.97 | 89.99 | -1.14% |
DAX 40 | 24,065.47 | 196.75 | -0.81% |
Dow JONES (US) | 44,130.98 | 330.30 | -0.74% |
FTSE 100 | 9,132.81 | 4.13 | -0.05% |
HKSE | 24,773.33 | 403.60 | -1.60% |
NASDAQ | 21,122.45 | 7.23 | -0.03% |
Nikkei 225 | 41,069.82 | 415.12 | 1.02% |
NZX 50 Index | 12,823.74 | 32.23 | -0.25% |
S&P 500 | 6,339.39 | 23.51 | -0.37% |
S&P/ASX 200 | 8,742.80 | 13.60 | -0.16% |
SSE Composite Index | 3,573.21 | 42.51 | -1.18% |